Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: A report from the Children's Cancer Group

Blood

Volumn 101, Issue 10, 2003, Pages 3809-3817

  Bostrom, Bruce C ^a   Sensel, Martha R ^b   Sather, Harland N ^b   Gaynon, Paul S ^b   La, Mei K ^b   Johnston, Katherine ^b   Erdmann, Gary R ^b   Gold, Stuart ^b   Heerema, Nyla A ^b   Hutchinson, Raymond J ^b   Provisor, Arthur J ^b   Trigg, Michael E ^b  

^a CHILDREN S ONCOLOGY GROUP   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; LIVER ENZYME; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; TIOGUANINE; VINCRISTINE; ANTINEOPLASTIC ANTIMETABOLITE;

ACUTE LYMPHOBLASTIC LEUKEMIA; AGITATION; ARTICLE; AVASCULAR NECROSIS; BACTEREMIA; BONE MARROW; BONE MARROW DISEASE; BRAIN HEMORRHAGE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RISK; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM; CHICKENPOX; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DYSESTHESIA; FEMALE; FEVER; HEMATURIA; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MUSCLE WEAKNESS; MYCOSIS; MYOPATHY; NEPHROLITHIASIS; NEUROPSYCHIATRY; NEUROTOXICITY; NEUTROPENIA; PANCREATITIS; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RESPIRATORY DISTRESS SYNDROME; SEDATION; SEIZURE; SEPSIS; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STREPTOCOCCUS INFECTION; STROKE; TESTIS DISEASE; VIRUS INFECTION; ACUTE LYMPHOCYTIC LEUKEMIA; BLOOD; BLOOD CELL COUNT; COMPARATIVE STUDY; DRUG ADMINISTRATION; GENETICS; INFANT; INTRASPINAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KARYOTYPING; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD;

6-MERCAPTOPURINE; ADMINISTRATION, ORAL; ANTIMETABOLITES, ANTINEOPLASTIC; BLOOD CELL COUNT; CHILD; CHILD, PRESCHOOL; DEXAMETHASONE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFANT; INJECTIONS, INTRAVENOUS; INJECTIONS, SPINAL; KARYOTYPING; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; METHOTREXATE; PREDNISONE;

EID: 0038264383     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-08-2454     Document Type: Article

References (58)

1. Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assign ment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996;14:18-24.
2. Tubergen DG, Gilchrist GS, O'Brien RT, et al. Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Children's Cancer Group phase III trial. J Clin Oncol. 1993; 11:527-537.
3. Balis FM, Lester CM, Chrousos GP, Heideman RL, Poplack DG. Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukemia. J Clin Oncol. 1987;5:202-207.
4. Gaynon PS, Lustig RH. The use of glucocorticoids in acute lymphoblastic leukemia of childhood: molecular, cellular, and clinical considerations. J Pediatr Hematol Oncol. 1995;17:1-12.
5. Jones B, Freeman AI, Shuster JJ, et al. Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia. Med Pediatr Oncol. 1991;19:269-275.
6. Veerman AJ, Hahlen K, Kamps WA, et al. Dutch Childhood Leukemia Study Group: early results of study ALL VI (1984-1988). Hamatol Bluttransfus. 1990;33:473-477.
7. Veerman AJ, Hahlen K, Kamps WA, et al. High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia: results of protocol ALL VI from the Dutch Childhood Leukemia Study Group. J Clin Oncol. 1996;14:911-918.
8. Silverman LB, Gelber RD, Kimball-Dalton V, Young ML, Sallan SE. Results of the Dana-Farber Cancer Institute (DFCI) Consortium Protocol 91-01 for Children with Acute Lymphoblastic Leukemia (ALL) [abstract]. Blood. 1998;92:483a.
9. Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood. 2001;97:1211-1218,
10. Lennard L, Lilleyman JS. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. 1989;7:1816-1823.
11. Schmiegelow K, Bruunshuus I. 6-Thioguanine nucleotide accumulation in red blood cells during maintenance chemotherapy for childhood acute lymphoblastic leukemia, and its relation to leukopenia. Cancer Chemother Pharmacol. 1990;26: 288-292.
12. Zimm S, Ettinger LJ, Holcenberg JS, et al. Phase I and clinical pharmacological study of mercaptopurine administered as a prolonged intravenous infusion. Cancer Res. 1985;45:1869-1873.
13. Adamson PC, Zimm S, Ragab AH, et al. A phase II trial of continuous-infusion 6-mercaptopurine for childhood solid tumors. Cancer Chemother Pharmacol. 1990;26:343-344.
14. Balis FM, Holcenberg JS, Poplack DG, et al. Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study. Blood. 1998;92:3569-3577.
15. Camitta B, Leventhal B, Lauer S, et al. Intermediate-dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B acute lymphocytic leukemia of childhood: a Pediatric Oncology Group study. J Clin Oncol. 1989;7:1539-1544.
16. Camitta B, Mahoney D, Leventhal B, et al. Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: a Pediatric Oncology Group study. J Clin Oncol. 1994;12:1383-1389.
17. Lange BJ, Bostrom BC, Cherlow JM, Sensel MG, La MK, Rackoff W, Heerema NA, Wimmer RS, Trigg ME, Sather HN. Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood. 2002;99:825-833.
18. Uckun FM, Muraguchi A, Ledbetter JA, et al. Biphenotypic leukemic lymphocyte precursors in CD2+CD19+ acute lymphoblastic leukemia and their putative normal counterparts in human fetal hematopoietic tissues. Blood. 1989;73:1000-1015.
19. Duttera MJ, Carolla RL, Gallelli JF, Gullion DS, Keim DE, Henderson ED. Hematuria and crystalluria after high-dose 6-mercaptopurine administration. N Engl J Med. 1972;287:292-294.
20. Heerema NA, Sather HN, Sensel MG, et al. Prognostic impact of trisomies of chromosomes 10, 17, and 5 among children with acute lymphoblastic leukemia and high hyperdiploidy (> 50 chromosomes). J Clin Oncol. 2000;18:1876-1887.
21. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York, NY: John Wiley and Sons; 1980.
22. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
23. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient, II: analysis and examples. Br J Cancer. 1977;35:1-39.
24. Cox DR. Regression models and life tables. J R Stat Soc B. 1972;34:187-220.
25. Gaynon PS, Carrel AL. Glucocorticosteroid therapy in childhood acute lymphoblastic leukemia. Adv Exp Med Biol. 1999;457:593-605.
26. Ekert H, Waters KD, Matthews RN, et al. A randomized study of corticosteroid and non-corticosteroid containing regimens in induction therapy of childhood ALL. Cancer Therapy and Control. 1990;1:87-95.
27. Henze G, Langermann HJ, Fengler R, et al. Acute lymphoblastic leukemia therapy study BFM 79/81 in children and adolescents: intensified reinduction therapy for patients with different risks for relapse. Klin Padiatr. 1982;194:195-203.
28. Henze G, Fengler R, Reiter A, Ritter J, Riehm H. Impact of early intensive reinduction therapy on event-free survival in children with low-risk acute lymphoblastic leukemia. Hamatol Bluttransfus. 1990;33:483-438.
29. Gaynon PS, Bostrom BC, Reaman GH, et al. Children's Cancer Group (CCG) initiatives in childhood acute lymphoblastic leukemia. Int J Pediatr Hematol Oncol. 1998;5:99-114.
30. Hann I, Vora A, Richards S, et al. Benefit of intensified treatment for all children with acute lymphoblastic leukaemia, results from MRC UKALL XI and MRC ALL97 randomised trials: UK Medical Research Council's Working Party on Childhood Leukaemia. Leukemia. 2000;14:356-363.
31. Cantrill HL, Waltman SR, Palmberg PF, Zink HA, Becker B. In vitro determination of relative corticosteroid potency. J Clin Endocrinol Metab. 1975; 40:1073-1077.
32. Ito C, Evans WE, McNinch L, et al. Comparative cytotoxicity of dexamethasone and prednisolene in childhood acute lymphoblastic leukemia. J Clin Oncol. 1996;14:2370-2376.
33. Kaspers GJ, Veerman AJ, Popp-Snijders C, et al. Comparison of the antileukemic activity in vitro of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. Med Pediatr Oncol. 1996;27:114-121.
34. Meikle AW, Tyler FH. Potency and duration of action of glucocorticoids: effects of hydrocortisone, prednisone and dexamethasone on human pituitary-adrenal function. Am J Med. 1977;63:200-207.
35. Hurwitz CA, Silverman LB, Schorin MA, et al. Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia. Cancer. 2000;88:1964-1969.
36. Mattano LA Jr, Sather HN, Trigg ME, Nachman JB. Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children's Cancer Group. J Clin Oncol. 2000;18:3262-3272.
37. Tan ML, Kardos G, Veerman AJP, van der Doesvan den Berg A, Kamps WA. Avascular osteonecrosis as side effect of treatment in childhood ALL may not be dependent upon dexamethasone dose. Med Pediatr Oncol. 1999;33:246.
38. Atkinson SA, Halton JM, Bradley C, Wu B, Barr RD. Bone and mineral abnormalities in childhood acute lymphoblastic leukemia: influence of disease, drugs and nutrition. Int J Cancer Suppl. 1998;11:35-39.
39. Strauss AJ, Su JT, Dalton VM, Gelber RD, Sallan SE, Silverman LB. Bony morbidity in children treated for acute lymphoblastic leukemia. J Clin Oncol. 2001;19:3066-3072.
40. Macdonald DR. Neurologic complications of chemotherapy. Neurol Clin. 1991;9:955-967.
41. Dropcho EJ, Soong SJ. Steroid-induced weakness in patients with primary brain tumors. Neurology. 1991;41:1235-1239.
42. Shuster J. Psychiatric complications of corticosteroids. Nursing. 1999;29:31.
43. Sutor B, Wells LA, Rummans TA. Steroid-induced depressive psychosis responsive to electroconvulsive therapy. Convuls Ther. 1996;12:104-107.
44. Wolkowitz OM. Prospective controlled studies of the behavioral and biological effects of exogenous corticosteroids. Psychoneuroendocrinology. 1994;19:233-255.
45. Waber DP, Carpentieri SC, Klar N, et al. Cognitive sequelae in children treated for acute lymphoblastic leukemia with dexamethasone or prednisone. J Pediatr Hematol Oncol. 2000;22:206-213.
46. Loring DW, Meador KJ. Corticosteroids and cognitive function in humans: methodological considerations. J Pediatr Hematol Oncol. 2000;22:193-196.
47. Pinkel D. Intravenous mercaptopurine: life begins at 40. J Clin Oncol. 1993;11:1826-1831.
48. Pieters R, Huismans DR, Loonen AH, et al. Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia. Lancet. 1991;338:399-403.
49. Lennard L, Rees CA, Lilleyman JS, Maddocks JL. Childhood leukaemia: a relationship between intracellular 6-mercaptopurine metabolites and neutropenia. Br J Clin Pharmacol. 1983;16:359-363.
50. Silberman T, Robison LL, Nesbit ME. Association between outcome in childhood acute lymphoblastic leukemia and amount of maintenance 6-mercaptopurine. Proc Amer Soc Clin Oncol. 1985;4: 166.
51. Dolan G, Lilleyman JS, Richards SM. Prognostic importance of myelosuppression during maintenance treatment of lymphoblastic leukaemia: Leukaemia in Childhood Working Party of the Medical Research Council. Arch Dis Child. 1989; 64:1231-1234.
52. Relling MV, Hancock ML, Boyett JM, Pui CH, Evans WE. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood. 1999;93:2817-2823.
53. Van Eys J, Berry D, Crist W, et al. Treatment intensity and outcome for children with acute lymphocytic leukemia of standard risk: a Pediatric Oncology Group Study. Cancer. 1989;63:1466-1471.
54. Kamen BA. Why more 6-mercaptopurine? Semin Hematol. 1991;28:12-14.
55. Mahoney DH Jr, Shuster J, Nitschke R, et al. Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group phase III trial. J Clin Oncol. 1998;16:246-254.
56. Van der Werff Ten Bosch J, Suciu S, Philippe N, et al. The value of 6-MP i.v. during maintenance treatment in childhood acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL): results of the randomized phase III trial 58881 of the EORTC Childhood Leukemia Cooperative Group (CLCG). Blood. 1999;94:628a.
57. Tolar J, Bostrom BC, Lee M, Sather H. Oral 6-mercaptopurine protects against fatal relapses in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group study CCG 1922. J Pediatr Hematol Oncol. 2000;22: 378.
58. Presta M, Rusnati M, Belleri M, Morbidelli L, Ziche M, Ribatti D. Purine analogue 6-methylmercaptopurine riboside inhibits early and late phases of the angiogenesis process. Cancer Res. 1999;59:2417-2424.